Nivolumab is a medication used as a first line treatment for inoperable or metastatic melanoma if no mutation in BRAF, and used as a second-line treatment if mutation in BRAF, as a second-line treatment for squamous non-small cell lung cancer, and as a second-line treatment for renal cell carcinoma.
It is a human IgG4 anti-PD-1 monoclonal antibody and works as a checkpoint inhibitor, blocking a signal that would have prevented activated T cells from attacking the cancer, thus allowing the immune system to clear the cancer.
It is administered through intravenous infusion every 2 weeks.
In 2016, it sold €200 million in Europe.
It has an immunogenicity rate of 12%.
Labs that test for drug level: